Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.06 USD
-0.01 (-0.33%)
Updated May 24, 2024 04:00 PM ET
After-Market: $3.05 -0.01 (-0.33%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 221 - 240 ( 398 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant/ARRS Receives CRL: Resubmission Anticipated by YE; Selloff Overdone
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant Rejected; Approval Unlikely to Require More Clinical Studies; Reducing PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Preview of Next Key Catalyst: Libervant/ARRS September 27, 2020 PDUFA Date
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Phase 1 AQST-108/ Anaphylaxis Trial Initiated; Data Expected in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-108 Pharmacokinetic Phase 1 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant Approval Decision Approaching; 2Q20 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D